Furthermore, autoimmune disorders, such as systemic lupus erythematosus (SLE), RA, polymyositis psoriatic arthropathy, sarcoidosis, autoimmune hemolysis, autoimmune thyroid disease, and immune thrombocytopenia, may occur during IFN-α therapy (8, 11). This evidence concerns the gene IFNA1 and systemic lupus erythematosus.